ovarian%20mass
OVARIAN MASS
Ovarian cysts are typically noted after clinical screening, or as a result of exam for a suspected pelvic mass, or an incidental finding in investigations done for other reasons.
Most ovarian masses manifest with few or mild nonspecific symptoms.
Ovarian masses in women of reproductive age are mostly benign but the risk of malignancy increases with age.
Ovarian cysts in the prepubertal patients especially after the first week of life are abnormal and likely to be neoplastic. In adolescent patients, majority of ovarian masses are functional cysts.

Pharmacotherapy

Monophasic Combination Oral Contraceptives (COCs)

  • Studies suggested that expectant management is as effective as hormonal treatment for the resolution of functional ovarian cysts
  • Patients may be offered oral contraceptives (OCs) if they are seeking contraception
  • Estrogen/progestogen therapy may be useful in patients with anovulatory cycles who need OCs to induce the next period
  • Many monophasic combination oral contraceptives are available. Please see the latest MIMS for specific formulations
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 27 Dec 2018
A lifestyle intervention programme focusing on healthy habits was associated with weight loss and better disease-free survival (DFS) among early breast cancer survivors, according to the SUCCESS C* study presented at SABCS 2018.
23 Dec 2018
TX-001HR, a fixed-dose combination of oestradiol and progesterone, yields clinically meaningful improvements in the frequency and/or severity vasomotor symptoms in menopausal women with a uterus, according to a study.
22 Dec 2018
Breastfeeding for more than 6 months after birth appears to be independently associated with a long-term decrease in waist circumference, reports a recent study.
Elaine Soliven, 11 Jul 2018

Adding bevacizumab to platinum-based chemotherapy significantly improves progression-free survival (PFS) in patients with recurrent ovarian cancer who were previously treated with first-line bevacizumab, according to the MITO16B - MaNGO OV2B - ENGOT OV17* study presented at ASCO 2018.